255 related articles for article (PubMed ID: 34808502)
21. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
Zhang Z; He CZ; Qin YQ; Liao JJ; Huang ST; Mo S; Li HM; Lin JY
Aging (Albany NY); 2020 Nov; 12(23):24255-24269. PubMed ID: 33234725
[TBL] [Abstract][Full Text] [Related]
22. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
23. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
24. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
[TBL] [Abstract][Full Text] [Related]
25. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
26. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
[TBL] [Abstract][Full Text] [Related]
27. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
[TBL] [Abstract][Full Text] [Related]
28. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Makol A; Kaur H; Sharma S; Kanthaje S; Kaur R; Chakraborti A
Clin Mol Hepatol; 2020 Jan; 26(1):45-53. PubMed ID: 31564085
[TBL] [Abstract][Full Text] [Related]
29. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
30. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
Liang XD; Dai YC; Li ZY; Gan MF; Zhang SR; Yin-Pan ; Lu HS; Cao XQ; Zheng BJ; Bao LF; Wang DD; Zhang LM; Ma SL
PLoS One; 2014; 9(6):e97739. PubMed ID: 24905462
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
Awan FM; Naz A; Obaid A; Ikram A; Ali A; Ahmad J; Naveed AK; Janjua HA
Sci Rep; 2017 Sep; 7(1):11448. PubMed ID: 28904393
[TBL] [Abstract][Full Text] [Related]
32. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
33. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
34. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
35. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.
Xu J; Ji L; Liang Y; Wan Z; Zheng W; Song X; Gorshkov K; Sun Q; Lin H; Zheng X; Chen J; Jin RA; Liang X; Cai X
Signal Transduct Target Ther; 2020 Dec; 5(1):298. PubMed ID: 33361760
[TBL] [Abstract][Full Text] [Related]
36. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Lai YL; Wang KH; Hsieh HP; Yen WC
J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
[TBL] [Abstract][Full Text] [Related]
37. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
[TBL] [Abstract][Full Text] [Related]
38. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA‑223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7.
Tang X; Yang W; Shu Z; Shen X; Zhang W; Cen C; Cao L; Zhang M; Zheng S; Yu J
Oncol Rep; 2019 Feb; 41(2):1231-1237. PubMed ID: 30535501
[TBL] [Abstract][Full Text] [Related]
40. PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells.
Lin JC; Yang PM; Liu TP
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]